Inclusion Criteria:  Pathological diagnosis of Advanced biliary malignancy The expected survival period is ≥3 months Patients with non-extensive metastases Except for the lesions to be radiotherapy, there is at least one measurable lesion tumor lesions are suitable for radiotherapy Have previously received platinum, gemcitabine or 5-FU drugs as first-line treatment, but have not used PD-1/PD-L1 monoclonal antibody treatment In the 7 days before enrollment, the Child Pugh score of liver function is 7 or less  Exclusion Criteria:  Patients with other malignant tumors Participated in other drug clinical trials within four weeks Clinical diagnosis of severe biliary obstruction or digestive tract obstruction in the past month Unstable angina pectoris Immunodeficiency Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia Patients who need to use corticosteroids Serious chronic autoimmune diseases Ulcerative enteritis, Crohn's disease and other inflammatory bowel diseases Inflammatory and chronic diarrheal diseases such as irritable bowel syndrome; Sarcoidosis or tuberculosis Patients with hypersensitivity to human or murine monoclonal antibodies Pregnant and lactating women